Bone Biologics wins new patent for recombinant protein process

Bone Biologics has received a US Patent Office notice of allowance of patent claims which protect a method of production for the UCB-1 recombinant protein that the company uses in the bone repair/regeneration technology in its lead product.

The patent broadly protects the manufacturing method for the UCB-1 (NELL-1) protein. The UCB-1 (NELL-1) protein is currently utilized with a carrier of DBX demineralized bone matrix which is produced by the Musculoskeletal Transplant Foundation (MTF).

Bruce Hazuka, CEO of Bone Biologics, said: The MTF is a world leader in tissue R&D, and has been both a financial and strategic partner to Bone Biologics over the past four years.

Bruce Stroever, CEO of MTF, said: We are very pleased with the progress that Bone Biologics has made in achieving each of their development milestones over the past four years and look forward to their continued progress toward FDA approval and commercialization on the timelines projected by the company.

Bone Biologics is a convergence biotechnology company focused in the Orthobiologics space. The target markets for the lead product unique UCB-1TM protein-based technologies of the company are bone and cartilage regeneration and lead product development and clinical studies are targeted on spinal fusion surgery.